From Financial Modeling Prep: 2025-05-05 10:12:00

Biogen Inc. reported mixed financial results for Q1 2025, with an adjusted EPS of $3.02, missing estimates. Revenues reached $2.43 billion, up 6% YoY, driven by new drug sales. Stock price is $122.81, down 0.58%.

Biogen is a key player in biotechnology, focusing on neurological diseases. Despite competition, the company aims for innovation. Analysts set a price target of $187, suggesting a potential upside of 52.77%.

Q1 2025 saw Biogen’s EPS at $3.02, an 18% decline YoY. Revenues hit $2.43 billion, up 6% YoY. New drug sales offset declines in key products. A collaboration with Stoke Therapeutics impacted earnings.

Investors are watching Biogen closely for signs of a turnaround. Stock price is $122.81, down 0.58%. Market cap is around $17.99 billion. Earnings report on May 1, 2025, will be crucial for stock movement.



Read more at Financial Modeling Prep:: Biogen Inc. (NASDAQ:BIIB) Faces Mixed Financial Re…